What is the normal (negative) QuantiFERON‑TB Gold Plus TB1 antigen interferon‑γ concentration value?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Normal QuantiFERON-TB Gold Plus TB1 Antigen Value

A QuantiFERON-TB Gold Plus test is considered negative (normal) when the TB1 antigen tube interferon-γ concentration is less than 0.35 IU/mL (after subtracting the Nil control value).

Interpretation Criteria

The interpretation of QuantiFERON-TB Gold Plus follows established FDA-approved criteria that apply to both TB1 and TB2 antigen tubes 1:

Negative Result (Normal)

  • TB Response (TB antigen minus Nil) < 0.35 IU/mL
  • This indicates no evidence of Mycobacterium tuberculosis infection

Positive Result

  • TB Response ≥ 0.35 IU/mL AND
  • TB Response ≥ 25% of the Nil control value (when Nil is 0.7-8.0 IU/mL)

Indeterminate Result

  • Mitogen control (positive control) ≤ 0.5 IU/mL (inadequate immune response), OR
  • Nil control > 8.0 IU/mL (excessive background)

Important Clinical Considerations

The Borderline Zone

While the official cutoff is 0.35 IU/mL, values between 0.20-0.99 IU/mL represent a clinically important "borderline zone" where test variability is highest 2, 3. Recent evidence shows:

  • 38.3% of borderline results (0.20-0.34 IU/mL) revert to convincingly negative (<0.20 IU/mL) on repeat testing without any cases of active TB developing within 2 years 2
  • False-positive results occur particularly in the 0.35-1.0 IU/mL range, especially with healthcare worker screening 3
  • Consider repeat testing for values between 0.35-1.0 IU/mL before committing patients to tuberculosis preventive therapy, particularly in low-risk populations

TB1 vs TB2 Tubes

The QuantiFERON-TB Gold Plus includes two antigen tubes:

  • TB1: Contains peptides from ESAT-6 and CFP-10 (primarily CD4+ T-cell response)
  • TB2: Contains shorter peptides from CFP-10 designed to elicit CD8+ T-cell response 1

The test is positive if EITHER TB1 OR TB2 meets positive criteria. However, TB2 contributes minimally to diagnosis—only 0.4% of tests show TB2 ≥0.35 IU/mL with TB1 <0.20 IU/mL 2.

Common Pitfalls to Avoid

  1. Automated analyzer inflation: The Liaison XL chemiluminescence analyzer produces systematically higher values than ELISA, with a bias of +0.21 IU/mL 4. This can convert borderline-negative results to false-positives. Consider confirming borderline-positive CLIA results (0.35-1.3 IU/mL) with ELISA, which reduces false-positives by 84.3% 4.

  2. High Nil values: When the Nil control is elevated (>0.7 IU/mL but <8.0 IU/mL), the TB Response must be both ≥0.35 IU/mL AND ≥25% greater than the Nil value to be considered positive 1.

  3. Low-risk populations: In settings with low TB prevalence, positive results <1.0 IU/mL have higher false-positive rates and warrant clinical correlation or repeat testing 3.

  4. Cannot distinguish recent from remote infection: Despite TB2 tube marketing, TB2-TB1 differences >0.6 IU/mL do NOT reliably identify recent TB exposure and should not be used for contact tracing decisions 5.

Clinical Context

Negative results alone cannot exclude TB infection in high-risk individuals (HIV-positive, children <5 years, immunosuppressed patients, or those with clinical/radiographic findings suggestive of active TB) 6. In these populations, a negative test should not prevent further evaluation or treatment if clinical suspicion remains high.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.